|Bid||13.60 x 1400|
|Ask||15.29 x 900|
|Day's Range||14.81 - 15.30|
|52 Week Range||11.83 - 33.44|
|Beta (3Y Monthly)||0.09|
|PE Ratio (TTM)||28.99|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.83|
Small-cap biopharma Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has withstood the market-wide sell-off witnessed in early August, thanks to the second-quarter report the company issued July 31. The company also reiterated its net product sales guidance for the fiscal year 2019. Notwithstanding the strong quarterly report and subsequent bounce, Vanda shares are still down about 43% year-to-date.
Biotech stocks came under pressure this week along with the broader market amid an earnings spate. The biggest news break was an FDA probe into data integrity issues with Novartis AG (NYSE: NVS )'s regulatory ...
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Clinical development progresses as the company’s shareholders and spectators watch for movement on another front: Its squabbles with the Food and Drug Administration.
Abiomed stock collapsed Thursday after the medical technology company lagged Wall Street's full-year guidance expectations by more than $20 million. Quarterly sales were also light.
Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Q2 2019 Total net product sales of $59.1 million , a 25% increase year over year - Q2 2019 Hetlioz® net product sales grew to $37.8 million , a 35% increase year over year - Vanda reiterates 2019 net ...
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Vanda Pharmaceuticals Inc. (VNDA) filed a derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, and waste of corporate assets beginning in November 2015. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders. If you suffered a loss as a result of Vanda's misconduct, click here.
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...
Conference Call and Webcast to Follow WASHINGTON , July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2019 on ...
Vanda Pharmaceuticals Inc. disclosed a note from federal regulators that pointed to deficiencies in its latest application for approval for a jet lag disorder treatment — but said the regulators didn't offer any more specifics. The D.C. biotech had applied for Food and Drug Administration approval to expand the label for its existing drug, Hetlioz, to be able to treat jet lag disorder. The company has been selling Hetlioz on the market since it was approved in 2014 to treat non-24-hour sleep-wake disorder, and it has fast become the company's top-selling product.
WASHINGTON, July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that on July 19, 2019, it received a notification from the U.S. Food and Drug Administration (FDA) stating that as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of Jet Lag Disorder, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. No deficiencies were disclosed by the FDA in this notification, and the FDA stated that this notification does not reflect a final decision on the information under review. In a letter dated December 19, 2018, the FDA had assigned a Prescription Drug User Fee Act ("PDUFA") target date for completion of its review by August 16, 2019.
The company’s latest experimental drug was tested on more than 100 patients with motion sickness traveling on the Pacific Ocean.
WASHINGTON , July 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness ...
NEW YORK, July 16, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Vanda Pharmaceuticals Inc. (NASDAQGM: VNDA) concerning possible breaches of.
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]
WASHINGTON , June 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference ...